Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of CagriSema on PK/PD of Warfarin and PK of Atorvastatin in Overweight or Obesity
NCT06289504Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2024
- Primary completion
- Oct 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cagrilintide and semaglutide in obesity, sponsored by Novo Nordisk. Primary endpoints: Area under the atorvastatin plasma concentration-time curve from time 0 to 72 hours and Area under the S-warfarin plasma concentration-time curve from time 0 to 168 hours. Started Feb 2024; status: completed.
02
Drugs
cagrilintidesemaglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06289504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06289504.